APO1 death receptor was not induced, indicating a cell-type specificity for gene transcription and, in agreement with previous results, 6 p21 Waf1 was not upregulated. Furthermore, the involvement of apoptotic intrinsic pathway was shown by induction of Noxa (Figure 1d ). These results indicate target genes transcriptional selectivity mediated by HIPK2 and the involvement of HIPK2 catalytic domain in this function. Therefore, to confirm the involvement of HIPK2-induced p53Ser46 phosphorylation in the transcription of KILLER/ DR5 gene, we overexpressed HIPK2 and K221R vectors in combination with wtp53 and S46A-mutant expression vectors in H1299 p53/null cells. We found that KILLER/DR5 expression levels were upregulated when HIPK2 was coexpressed with wtp53, but not with p5346A mutant (Figure 1e ). Similarly, K221R vector coexpressed with wtp53 failed to upregulate both KILLER/DR5 gene and the already known p53AIP1 gene. Finally, we found that HIPK2-induced caspase-3 and -8 activities were strongly impaired by inactivating KILLER/DR5 function using siRNA ( Figure 1f ). As expected, TUNEL assay revealed reduction of HIPK2-induced apoptosis in the absence of KILLER/DR5 (Supplementary Figure S3a and  b ). Therefore, we tested the involvement of Noxa (intrinsic pathway) in HIPK2-induced relative caspase-3 and -8 activities and apoptosis. We overexpressed HIPK2 in 2008 cells, following abolishment of endogenous Noxa by siRNA and found a strong reduction of caspase-3 activity, while caspase-8 activity was not affected; in agreement siRNA for Noxa function, reduced HIPK2-induced apoptosis of about 38% (Supplementary Figure S4a and S4b).
Altogether, these data demonstrate, for the first time, that exogenous HIPK2 can induce apoptosis through caspase-8 activation and that HIPK2-induced p53S46 phosphorylation may regulate the expression of KILLER/DR5 gene, involved in caspase-8/extrinsic pathway activation. However, we also show that the mitochondrial intrinsic pathway is induced by HIPK2 through Noxa, likely explaining why inhibition of caspase-8 does not completely abolish HIPK2-induced apoptosis. These are important findings because the initiator caspases, including caspase-8 and -9, appear to have some specificity for different types of upstream signals as well as preferred downstream substrate procaspases. Moreover, components of cell apoptotic machinery are frequently altered in cancer and disruption of apoptotic pathways may be involved in tumor formation, regression, and chemoresistance. The fact that HIPK2/p53Ser46 participates in both the extrinsic and the intrinsic pathways of caspases activation supports the idea that there are multiple downstream effectors of p53 involved in cell death and strengthen the role of this specific p53Ser46 post-translational modification in selective activation of apoptotic target genes. Thus, agents that induce phosphorylation of p53 at Ser46 will favor the transcriptional repertoire of p53 towards proapoptotic genes, thereby favoring death. Dear Editor, Prothymosin-a1 (ProTa), a highly acidic nuclear protein of the a-thymosin family, has multiple functions both within and outside of the cell. 1 ProTa plays a cytoprotective role by inhibiting apoptosome formation, 2 and it has cell proliferative activity as an extracellular signaling molecule. 1 Recently, we found that ProTa is released upon necrotic stress and protects cells from neuronal death through activation of a putative G i/o -coupled receptor coupled to phospholipase C and protein kinase Cb II . (1 mg each) was given into the subarachnoid space through a parietal bone, 30 min before MCAO stress. Results represent the incidence of activated caspase 3 (green) and PI staining (red). *Po0.05. (r) Evidence for Myc-tagged ProTa transport through the blood-brain barrier after ischemic stress. Myc-tagged ProTa at 1 mg/kg (i.p.) was given to rats 30 min after reperfusion, and proteins (30 mg) from the cortex isolated 2.5 h later were used for Western blot analysis Following stroke or traumatic damages, both necrotic and apoptotic neuronal death cause loss of functions including memory, sensory perception and motor skills. 4, 5 Necrosis occurs during the early stages of stroke and of the affected area expands with time, 6 whereas the apoptosis occurs with some delay, but may also have a potential role in restricting the spread of irretrievable damage. 6, 7 There have been many attempts to find compounds that inhibit apoptosis, but the protective potencies of these compounds against ischemic damage in vivo remain limited. [8] [9] [10] [11] This may be related to the possibility that rapid and expanding necrosis largely contributes to the total loss of brain neurons following ischemia. Thus, rapid treatment of stroke is currently emphasized. [11] [12] [13] Compared with the machinery involved in apoptosis, necrosis is a more passive process, in which energy failure leads to a rupture of the plasma membrane with concomitant loss of intracellular proteins and ions. 6 However, no compounds that inhibit necrosis are known. Here, we demonstrate that ProTa has potential therapeutic utility against the necrosis component of stroke.
In the focal ischemic model of middle cerebral artery occlusion (MCAO, 1 h) followed by reperfusion in the rat, a marked loss of triphenyltetrazolium chloride (TTC) staining, which detects the presence of mitochondrial enzymes, was observed specifically in the ipsilateral regions of the cerebral cortex, hippocampus and striatum at 24 h after reperfusion (Figures 1a-1d ). Systemic administrations of recombinant rat ProTa (rrProTa, 100 mg/kg, i.p.) at 30 min and 3 h after reperfusion, largely reversed this brain damage and suppressed ischemia-induced motor dysfunction, evaluated by a so-called clinical score, 14 and lethality (Figures 1f and 1g) . It should be noted that ProTa protected the brain from cell death and motor dysfunction when administered as a single injection (at 30 min or 3 h after reperfusion) or in a pair of later injections (at 3 and 6 h after reperfusion). In a sublethal global ischemic model using both common carotid artery occlusions (BCCAO, 30 min), there were marked losses of neurons in the pyramidal cell layers and dentate gyri of surviving mice at 28 days after occlusion (Figure 1(h) . A single systemic (i.p.) injection of recombinant mouse ProTa (rmProTa) at 100 mg/kg 24 h after occlusion completely prevented brain damage, learning and memory deficits in the step-through passive avoidance task, and lethality (Figures 1i-k) . Significant prevention was also observed with rmProTa at a very low dose, 1 mg/kg (i.p.).
By cytochemical analysis, both necrosis and apoptosis were observed in damaged brain regions 24 h after MCAO, when cell death was evaluated by in vivo propidium iodide and activated-caspase 3 staining. Systemic rrProTa injection (i.p.) markedly inhibited both necrotic and apoptotic cell death (Figures 1l-1o) .
It should be noted that ProTa inhibited both necrosis and apoptosis following ischemia. This finding contrasts with our recent study, in which ProTa was shown to inhibit necrosis by restoring the reduced membrane translocation of glucose transporters under ischemic conditions in a primary culture of cortical neurons, but to cause apoptosis through upregulation of proapoptotic Bax and Bim. 3 However, complete inhibition of cell death was observed when ischemic neurons were cotreated with ProTa and antiapoptotic neurotrophins, the expression levels of which are upregulated in in vivo ischemic models. 15 In fact, the treatment with anti-BDNF or anti-EPO IgG (1 mg each) into the subarachnoid space through a parietal bone, 30 min before MCAO stress, reversed ProTainhibited apoptosis, but not necrosis (Figures 1p and q) . A single or paired injection of ProTa through a systemic route is sufficient to completely prevent damage in brain ischemic models. As shown in Figure 1r , a significant amount of Myc-tagged rrProTa, which had been administered i.p., was detected in the cortex 3 h after MCAO stress. The neuroprotective actions of ProTa administered through systemic routes are likely to be due to the transient disruption of the blood-brain barrier in the ischemic brain. 16 It is worth to note that the neuroprotective actions of ProTa were observed when injected systemically 3 h after the ischemia, a time point within the therapeutic window for the treatment of stroke with tissue plasminogen activator. The fact that neurons are the major sites of action for ProTa is also expected to be advantageous in the treatment of stroke.
The paper by Shiau et al. 17 described that added ProTa is incorporated into the cell and nuclei to 'enhance' the cytokine gene transcription and increase the infarct volume through inflammatory actions, whereas ProTa mutant lacking nuclear localizing sequence (NLS) 'inhibits' it. As shown in the Figure 1r , Myc-ProTa incorporated into the brain does not seem to be degraded and lose C-terminal NLS. Therefore, the finding by Shiau et al. 17 is unlikely related to the ProTa-induced cell death inhibition in this study. Furthermore, in our previous study, 3 there was no significant difference in the survival activity between ProTa and its mutant lacking C-terminal NLS.
Thus, ProTa is a unique cell death regulatory molecule, in that it converts irretrievable necrotic cell death into controllable apoptosis. Because this apoptosis can be inhibited by growth factors secreted upon ischemic stress, it is expected that ProTa may have an overall neuroprotective roles in the treatment of stroke.
